Cefsulodin

This image is provided by the National Library of Medicine.

WikiDoc Resources for Cefsulodin
Articles
Most recent articles on Cefsulodin Most cited articles on Cefsulodin Review articles on Cefsulodin Articles on Cefsulodin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefsulodin Images of Cefsulodin Photos of Cefsulodin Podcasts & MP3s on Cefsulodin Videos on Cefsulodin
Evidence Based Medicine
Cochrane Collaboration on Cefsulodin Bandolier on Cefsulodin TRIP on Cefsulodin
Clinical Trials
Ongoing Trials on Cefsulodin at Clinical Trials.gov Trial results on Cefsulodin Clinical Trials on Cefsulodin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefsulodin NICE Guidance on Cefsulodin NHS PRODIGY Guidance FDA on Cefsulodin CDC on Cefsulodin
Books
Books on Cefsulodin
News
Cefsulodin in the news Be alerted to news on Cefsulodin News trends on Cefsulodin
Commentary
Blogs on Cefsulodin
Definitions
Definitions of Cefsulodin
Patient Resources / Community
Patient resources on Cefsulodin Discussion groups on Cefsulodin Patient Handouts on Cefsulodin Directions to Hospitals Treating Cefsulodin Risk calculators and risk factors for Cefsulodin
Healthcare Provider Resources
Symptoms of Cefsulodin Causes & Risk Factors for Cefsulodin Diagnostic studies for Cefsulodin Treatment of Cefsulodin
Continuing Medical Education (CME)
CME Programs on Cefsulodin
International
Cefsulodin en Espanol Cefsulodin en Francais
Business
Cefsulodin in the Marketplace Patents on Cefsulodin
Experimental / Informatics
List of terms related to Cefsulodin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Cefsulodin is a third-generation cephalosporin antibiotic with specific activity against Pseudomonas aeruginosa. It has no significant activity against other Gram-negative bacteria and very limited activity against Gram-positive bacteria and anaerobic bacteria. Cefsulodin was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. In 2002, Takeda stopped production of cefsulodin. Many years of low-stability cefsulodin production has led to a widespread reduction of laboratory and research uses. Current attempts (i.e. IDEXX Laboratories) of increasing purity and stability of cefsulodin center around recrystallization. Typically, the process entails: Cefsulodin is dissolved in an organic solvent, sodium ions, water, or any mixture thereof, then subsequently recrystallized through separation of the unwanted fraction. Recently, TOKU-E has found the main cause of cefsulodin instability stems from one key impurity in 7-aminocephalosporanic acid, a raw material used in the synthesis of cefsulodin. To produce high-purity, high-stability cefsulodin, TOKU-E uses industrial HPLC to remove significant quantities of this impurity in 7-ACA and thus produces ultrapure, ultrastable, and ultrapotent cefsulodin.

General use

Cefuslodin is most commonly used in cefsulodin-irgasan-novobiocin agar to select for Yersinia microorganisms. This agar is most often used in water and beverage testing.

Susceptibility data

The following represents MIC susceptibility data for various P. aeruginosa strains.

• Pseudomonas aeruginosa PA13 (resistant strain): 32 μg/ml
• Pseudomonas aeruginosa (wild-type, susceptible): 4 - 8 μg/ml